Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Cybin (CYBN) announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

PharmacoEconomics: “Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.” GoodTherapy ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...